Exome sequencing identifies \(\text{BRAF}\) mutations in papillary craniopharyngiomas

Priscilla K Brastianos, Amaro Taylor-Weiner, Peter E Manley, Robert T Jones, Dora Schubert, Ashwini Sunkavalli, Nick Shillingford, Monica L Calicchio, Hart G W Lidov, Hala Taha, Maria Martinez-Lage, Mariarita Santini, Phillip B Storm, John Y K Lee, James N Palmer, Nithin D Adappa, R Michael Scott, Ian F Dunn, Edward R Laws Jr, Chip Stewart, Keith L Ligon, Mai P Hoang, Paul Van Hummelen, William C Hahn, David N Louis, Adam C Resnick, Mark W Kieran, Gad Getz, Sandro Santagata

Craniopharyngiomas are epithelial tumors that typically arise in the suprasellar region of the brain. Patients experience substantial clinical sequelae from both extension of the tumors and therapeutic interventions that damage the optic chiasm, the pituitary stalk and the hypothalamic area. Using whole-exome sequencing, we identified mutations in \(CTNNB1\) (\(\beta\)-catenin) in nearly all adamantinomatous craniopharyngiomas examined (11/12, 92%) and recurrent mutations in \(BRAF\) (resulting in p.Val600Glu) in all papillary craniopharyngiomas (3/3, 100%). Targeted genotyping revealed \(BRAF\) p.Val600Glu in 95% of papillary craniopharyngiomas (36 of 39 tumors) and mutation of \(CTNNB1\) in 96% of adamantinomatous craniopharyngiomas (51 of 53 tumors). The \(CTNNB1\) and \(BRAF\) mutations were clonal in each tumor subtype, and we detected no other recurrent mutations or genomic aberrations in either subtype. Adamantinomatous and papillary craniopharyngiomas harbor mutations that are mutually exclusive and clonal. These findings have important implications for the diagnosis and treatment of these neoplasms.

Craniopharyngiomas occur at an average age-adjusted incidence rate of 0.18 per 100,000 (ref. 5). There are two main subtypes of craniopharyngiomas—the adamantinomatous form that is more common in children and the papillary form that occurs predominantly in adults. Located in or above the sella turcica, craniopharyngiomas grow adjacent to the optic chiasm and often extend to involve the hypothalamus, cranial nerves, ventricular system, visual pathways and major blood vessels at the base of the brain. Curative surgery is exceedingly difficult, and resection can contribute to complications. The spectrum of complications include visual defects, severe headaches, pan-hypopituitarism, impaired intellectual function and wide-ranging hypothalamic dysfunction leading to sleep disorders, abnormal thermoregulation and diabetes insipidus, as well as to hyperphagia and uncontrollable obesity. Aptly, Harvey Cushing, the father of neurosurgery, who introduced the term ‘craniopharyngioma’ declared them “the most formidable of intracranial tumors.”

Knowledge of the molecular mechanisms that drive craniopharyngiomas remains limited, which has hampered the development of systemic therapies for this type of tumor. Mutations in exon 3 of \(CTNNB1\) (\(\beta\)-catenin), which encodes a degradation targeting motif, have been described in adamantinomatous craniopharyngiomas, occurring in 60–75% of patients in most published series. However, mutations that drive the growth of papillary craniopharyngiomas have not been identified. To that end, we performed massively
parallel sequencing of 15 craniopharyngiomas from both subtypes and targeted genotyping in samples from 95 additional patients.

We first used whole-exome sequencing to analyze the DNA from a discovery cohort of adamantinomatous (n = 12) and papillary (n = 3) craniopharyngiomas (Supplementary Table 1). As craniopharyngiomas are often heterogeneous tumors with nests of tumor cells interspersed between large amounts of reactive tissue and stromal cells, we expected the mutations to have low allelic fractions (i.e., the mutations might only be found in a small subset of the sequenced cells because of substantial contamination by normal cells). Thus, we analyzed the sequencing data with a subset of the sequenced cells because of substantial contamination and low allelic fractions (i.e., the mutations might only be found in a small tissue and stromal cells, we expected the mutations to have low allelic fractions (i.e., the mutations might only be found in a small subset of the sequenced cells because of substantial contamination by normal cells).

In consonance with the benign histology of these tumors, we identified only a relatively small number of nonsynonymous somatic mutations in both craniopharyngioma subtypes when compared to large cohorts of other tumor types (Fig. 1). The nonsynonymous mutation rate of 0.9 per Mb in the craniopharyngioma samples was similar to that found in a number of pediatric tumors, as well as that in low-grade tumors in adults, for example, World Health Organization–classified grade I meningioma (Fig. 1). 58% of the mutations were cytosine to thymidine at CpG dinucleotides, which is consistent with spontaneous deamination and not a carcinogen-induced process (Fig. 1). As we anticipated, the allelic fraction for many of the mutations was very low (median, 3%; range, 0.96–48%).

The most frequently mutated gene was CTNNB1, with mutations in this gene present in 11 of 12 adamantinomatous craniopharyngiomas (Fig. 2 and Supplementary Tables 2–4). These events overlapped with mutations previously described in this tumor type and were located in exon 3 exclusively (Fig. 2). In addition, adamantinomatous craniopharyngiomas harbored isolated mutations in genes that have been implicated previously in cancer (Fig. 2). We identified mutations in genes listed in the Cancer Gene Census (BCOR, CRTC3, MITF and PRDM1) and epigenetic regulation (KDM5A and SMARCA4), as well as in DNA repair (BRCA2) (Fig. 2). We detected additional mutations in genes not listed in the Cancer Gene Census but that have described roles in cancer, including genes involved in chromatin remodeling and regulation of transcription (including ASC22, KATS, PIWIL1, SINA and SMCA), cell cycle and DNA repair (including ATR, BARD1, CDC25B, HB1, RBBP8 and RETL1) and cell adhesion (ITGA3, PKD1, PKD1L1, PODN, ROCK1 and RPTN). However, many of these may be passenger mutations that do not contribute to tumor initiation or progression.

All three of the papillary craniopharyngiomas in our discovery set harbored mutations (c.1799T > A) in the well-established oncogene BRAF (resulting in p.Val600Glu) that have been shown to constitutively activate this serine-threonine kinase that regulates MAP kinase (also called ERK) signaling and affects cell division and differentiation (Fig. 2). None of the three papillary craniopharyngiomas had mutations in CTNNB1. Although two of these samples were resected from adults (31 and 52 years old), one of the samples was from a rare papillary craniopharyngioma that occurred in a child (9 years old), suggesting a similar pathogenesis between pediatric and adult papillary craniopharyngiomas. We did not identify mutations in other genes listed in the Cancer Gene Census in these tumors, but we did note isolated mutations in other genes with potential roles.
in cancer, including genes encoding chromatin remodeling factors (CHD5 and CHD6)\textsuperscript{17} and cell adhesion molecules (CDH26 and PTPRT)\textsuperscript{18} and one gene (KIAA1549) that is fused to BRAF in most cases of pilocytic astrocytoma\textsuperscript{19,20}. These mutations, similarly to some of those found in adamantinomatous craniopharyngiomas, may also be passenger mutations.

We used MutSig\textsuperscript{14} to analyze the list of mutations identified in our discovery cohort of 15 cases to identify genes that are significantly mutated. Although our cohort is small compared to those from other genomic studies\textsuperscript{14} (Fig. 1), the prevalence of mutations in CTNNB1 and BRAF was so high that we were readily able to detect these mutations as being statistically significant (Fig. 2).

To validate our findings, we used targeted genotyping approaches to analyze an additional 98 craniopharyngioma samples (from 95 different patients) for mutations in the most commonly mutated genes in our discovery cohort—BRAF and CTNNB1. We also performed immunohistochemistry (IHC) using an antibody (VE1) that selectively recognizes the BRAF p.Val600Glu mutant epitope and not the wild-type epitope from BRAF\textsuperscript{21}. In addition, we evaluated the activation status of β-catenin using an antibody that allowed us to detect nuclear (activated) and membranous (inactivated) β-catenin\textsuperscript{12}. In total, our validation cohort consisted of 39 papillary craniopharyngioma tumors from 36 different patients and 59 adamantinomatous craniopharyngioma tumors, each from a different patient (Supplementary Table 1). Although we detected CTNNB1 mutations in the adamantinomatous craniopharyngioma samples (51 of 53 samples, 96%), none of these samples harbored BRAF mutations (resulting in p.Val600Glu, p.Val600Asp, p.Val600Leu, p.Val600Met or p.Val600Lys). We identified cytoplasmic and nuclear β-catenin by IHC in all of the adamantinomatous samples tested, but β-catenin was localized exclusively to the cytoplasmic membrane in all papillary craniopharyngioma samples tested (Fig. 3 and Supplementary Table 1).

Remarkably, by targeted genotyping and IHC, we detected the p.Val600Glu alteration in 34 of the 36 patients with papillary craniopharyngiomas (94.4%) (Supplementary Table 1).

The allelic fraction of mutations (including those in BRAF and CTNNB1) in our whole-exome data was low (Fig. 2a and Supplementary Table 2). This raised the possibility of genetic heterogeneity in our tumor samples. To assess this possibility, we used a recently developed computational method (Online Methods) that corrects for tumor purity and estimates the fraction of cancer cell nuclei that harbor a particular mutation (cancer cell fraction; CCF). Although these methods demonstrated that most of the somatic mutations identified in our samples were indeed subclonal, we found that the mutations in BRAF and CTNNB1 were clonal (i.e., they were present in all tumor cells) in the analyzed samples (Figs. 2a and 4a and Supplementary Table 2).

To further validate our analysis of intratumor heterogeneity, we reviewed the pattern and distribution of BRAF staining in the

Figure 2 Mutations in adamantinomatous and papillary craniopharyngiomas. (a) The number of mutations per megabase in each of 15 craniopharyngioma whole-exome sequencing data sets (12 adamantinomatous and 3 papillary samples). Specific genes are shown that bear nonsynonymous somatic mutations in genes listed in the Cancer Gene Census\textsuperscript{16}. Right, false discovery rate q values providing the significance of the mutations in each listed gene. Cancer-relevant genes that are not listed in the Cancer Gene Census are not shown. The q value is an evaluation of whether a gene is significantly mutated above the expected basal rate of mutation. The q values for BRAF and CTNNB1 are both <0.00001. The q values of the other genes in the plot are equal to 1. A full list of mutated genes is provided in Supplementary Table 2. Colors indicate the type of genetic change identified. Only one mutation is indicated, even if multiple mutations were found in a particular gene. The CCF (0–1.0) for each indicated mutation is shown in white in the corresponding box. The allelic fraction for mutations in each sample is shown in the box plot, with the median indicated by a red line (the allelic fraction for each mutation is listed in Supplementary Table 2). The bottom and the top of the boxes represent the first and third quartiles, respectively; the ends of the whiskers represent 1 s.d. above and below the median of the data; and the red dots represent outlier points not included in the whiskers. For each sample, the relative frequencies of six different possible base-pair substitutions are shown at the bottom. Syn., synonymous; nonsyn., nonsynonymous. (b) Schematics for CTNNB1 and BRAF indicating the location of the identified mutations (11 in CTNNB1 and 3 in BRAF).

Figure 3 β-catenin localization is different in adamantinomatous and papillary craniopharyngiomas. Shown are IHCs for β-catenin. (a) β-catenin is localized to the cytoplasm and the nucleus in an adamantinomatous craniopharyngioma. (b) β-catenin is localized to the cell membrane in a papillary craniopharyngioma. Scale bars, 50 μm. β-catenin localization in many samples from the discovery and validation cohort is reported in Supplementary Table 1.
craniopharyngioma samples (Supplementary Table 1). Using the antibody selective for BRAF p.Val600Glu, we did not detect BRAF p.Val600Glu in the adamantinomatous craniopharyngioma samples (Supplementary Table 1) or in two of the papillary craniopharyngioma samples with wild-type BRAF that we tested (Fig. 4b). In the genetically confirmed BRAF p.Val600Glu mutant samples, however, we observed widespread immunoreactivity across the tumor cell population. In these samples, lymphocytes and stromal cells of the fibrovascular core of the tumors were not immunoreactive, but the squamopapillary tumor epithelium stained diffusely for BRAF p.Val600Glu. This observation supports the conclusion that BRAF mutations are present uniformly throughout the neoplastic epithelial cells.

Our whole-exome sequencing data of craniopharyngiomas demonstrates that the adamantinomatous and papillary subtypes have distinct molecular underpinnings, each driven principally by mutations in a single well-established oncogene: CTNNB1 (β-catenin) in the adamantinomatous form and BRAF in the papillary form, independent of age.

These mutations appear to be critical events in the pathogenesis of these tumors for several reasons. First, the high prevalence of mutations in CTNNB1 and BRAF in craniopharyngiomas occurs among an overall paucity of additional mutations, supporting that these particular mutations are likely instrumental to the growth of these tumors. Second, the mutations are clonal and segregate perfectly with their respective histologic subtypes, indicating that they are defining genetic aberrations. Moreover, the frequencies of these CTNNB1 and BRAF mutations are much higher in craniopharyngiomas than in most other tumor types that bear these mutations.

Given the mutual exclusivity of mutations in BRAF and CTNNB1, immunohistochemistry for BRAF p.Val600Glu and β-catenin could be used to routinely distinguish papillary from adamantinomatous craniopharyngiomas and thereby direct patients to appropriate clinical trials. Whereas agents that target WNT signaling remain craniopharyngiomas and thereby direct patients to appropriate molecularly guided therapeutics for the treatment of these formidable brain tumors.

METHODS

Methods and any associated references are available in the online version of the paper.

Accession codes. Data, including sequence data and analyses, will be available for download from the database of Genotypes and Phenotypes (dbGaP) under accession phs000696.v1.p1.

Note: Any Supplementary Information and Source Data files are available in the online version of the paper.

ACKNOWLEDGMENTS

We thank M. Ducar for his assistance with genomic analyses; S. Chauvin for project management; L. Brown and H. Malkin for assisting with sample collection; T. Woo, B. Rich, R. Machaidze and D. Feldman for technical assistance; N. Stransky for the design of Figure 2a; and H. Taylor-Weiner and C.H. Brastianos for critical review of the manuscript. This work was supported by the Jared Branfman Sunflowers for Life Fund for Pediatric Brain and Spinal Cancer Research, the Pediatric Low-Grade Astrocytoma (PLGA) Program (S.S., W.C.H. and Charles D. Stiles), Pedals for Pediatrics and the Clark Family (P.E.M. and M.W.K.), the Stahl Family Charitable Foundation (P.E.M.), the Stop & Shop Pediatric Brain Tumor Program (P.E.M. and M.W.K.), the Pediatric Brain Tumor Clinical and Research Fund (P.E.M. and M.W.K.), the Children’s Brain Tumor Foundation and the V Foundation (S.S.). S.S. is supported by grant K08 NS064168.
and P.K.B. is supported by grant K12 CA090354-11, the Brain Science Foundation, Susan G. Komen for the Cure, the Terri Brodeur Breast Cancer Foundation, the Conquer Cancer Foundation and the American Brain Tumor Association.

**AUTHOR CONTRIBUTIONS**

P.K.B., P.E.M., M.W.K., G.G. and S.S. designed the study. P.K.B., A.T.-W., C.S., G.G. and S.S. wrote the study. A.T.-W., P.K.B., C.S., A.R.T. and G.G. performed computational analyses. P.V.H. supervised the sequencing. S.S. and D.N.L. reviewed the histopathology, and S.S., D.N.L. and M.P.H. coordinated and reviewed the immunohistochemistry. K.L.L. managed the tissue repository. R.T.I., L.A.B., A.S., N.S., L.S. and M.I.C. coordinated sample acquisition, processed samples and coordinated and performed exome and targeted sequencing. P.K.B., W.C.H., D.D.-S., D.N.L., A.C.R., M.W.K., G.G. and S.S. supervised the study. H.G.W.L., H.L.H.A., D.D.-S., D.N.L., A.C.R., M.W.K., G.G. and S.S. identified and provided materials for sequencing and validation, as well as clinical information. M.I.S. provided the code and the data to generate Figure 1. All authors discussed the results and implications and edited the manuscript.

**COMPETING FINANCIAL INTERESTS**

The authors declare no competing financial interests.

Reprints and permissions information is available online at http://www.nature.com/reprints/index.html.

1. Louis, D.N., Ohgaki, H., Wiestler, O.D. & Cavenee, W.K. WHO Classification of Tumours of the Central Nervous System 238–240 (International Agency for Research on Cancer, 2007).
2. Crotty, T.B. et al. Papillary craniopharyngioma: a clinicopathological study of 48 cases. J. Neurolingu. 83, 206–214 (1995).
3. Duff, J. et al. Long-term outcomes for surgically resected craniopharyngiomas. Neurosurgery 46, 291–302, discussion 302–305 (2000).
4. Weiner, H.L. et al. Craniopharyngiomas: a clinicopathological analysis of factors predictive of recurrence and functional outcome. Neurosurgery 35, 1001–1010, discussion 1010–1011 (1994).
5. Dolecek, T.A., Propp, J.M., Stroup, N.E. & Kruchko, C. CBTRUS statistical report: 2013. Nat. Cancer Inst. Monogr. 46, 814–821 (2004).
6. Buslei, R. et al. Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumors originating from the sellar region. Acta Neuropathol. 109, 589–597 (2005).
7. Sekine, S. et al. Craniopharyngiomas of adamantinomatous type harbor β-catenin gene mutations. Am. J. Pathol. 161, 1997–2001 (2002).
8. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
9. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
10. Vazquez, L. et al. Genomic sequencing of meningiomas identifies oncogenic NF1 and KIT mutations. Nat. Genet. 45, 285–289 (2013).
11. Futeal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).
12. Jones, D.T. et al. Oncogenic RAFI rearrangement and a novel BRAF mutation as alternatives to KIAA1549-BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28, 2119–2123 (2009).
13. Vartanian, L.E. et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 4, e7887 (2009).
ONLINE METHODS
Sample selection and preparation. The study was reviewed and approved by the human subjects institutional review boards of the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, Broad Institute of Harvard and MIT, Boston Children’s Hospital, Johns Hopkins Hospital, Children’s Cancer Hospital Egypt and Children’s Hospital of Philadelphia. Written informed consent was obtained from all participants whose tumor samples were subjected to whole-exome sequencing. Histologic diagnosis was reconfirmed on all samples by a board-certified neuropathologist (S.S.), and representative fresh-frozen and paraffin-embedded blocks with estimated purity ≥10% were selected. DNA was extracted from tissue shavings of frozen tissue or 1-mm core-punch biopsies (Milteex, 33-31A-P/25) from formalin-fixed paraffin-embedded tissue and from buffy coat preparations of paired blood using standard techniques (QIAGEN, Valencia, CA). The DNA was then quantified using PicoGreen dye (Invitrogen, Carlsbad CA). Mass spectrometric genotyping with a well-established 48-SNP panel was used to confirm the identity of tumor-normal pairs (Sequenom, San Diego, CA)36.

Whole-exome sequencing and analyses. Whole-exome sequencing was performed as previously described35. In brief, DNA was fragmented by sonication (Covaris Inc., Woburn, MA) to 150 bp and further purified using Agencourt AMPure XP beads. 50 ng of size-selected DNA was then ligated to specific adaptors during library preparation (Illumina TrueSeq, Illumina Inc., San Diego, CA). Each library was made with sample-specific barcodes and quantified by quantitative PCR (Kapa Biosystems, Inc., Woburn, MA), and two libraries were pooled to a total of 500 ng for exome enrichment using the Agilent SureSelect hybrid capture kit (Whole Exome_v2 and Whole Exome_v4, 44 Mb; Agilent Technologies, Santa Clara, CA). Each library was made with sample-specific barcodes and quantified by quantitative PCR (Kapa Biosystems, Inc., Woburn, MA), and two libraries were pooled to a total of 500 ng for exome enrichment using the Agilent SureSelect hybrid capture kit (Whole Exome_v2 and Whole Exome_v4, 44 Mb; Agilent Technologies, Santa Clara, CA). Several captures were pooled further and sequenced in one or more lanes to a final equivalent of two exomes per lane on a HiSeq 2500 system (Illumina Inc, San Diego, CA).

Read pairs were aligned to the hg19 reference sequence using the Burrows-Wheeler Aligner37, and sample reads were demultiplexed using Picard tools. Data were sorted and duplicate-marked using SAMtools and Picard. Bias in base quality score assignments due to flowcell, lane, dinucleotide context and machine cycle were analyzed and recalibrated, and local realignment around insertions or deletions (indels) was achieved using the Genome Analysis Toolkit (GATK)38,39. Somatic variant calling was performed within the Firehose environment40 using MuTect3. All sample pairs passed a quality-control pipeline to test for any tumor-normal and interindividual mixups by comparing insert-size distribution and copy-number profile as described previously41.

Somatic mutations and short indels were called and post filtered using MuTect3 and Indelocator40,41. These were annotated to genes and compared to events in the Catalogue of Somatic Mutations in Cancer (COSMIC) using Oncotator, and spurious calls caused by mismapping and other previously identified systematic errors were removed using an established list of known problematic sites15,40,42,43. MutSig14 was used to determine the significance of mutated genes. MutSig compares observed mutations against expected sequence-specific, context-specific, tumor-specific and gene-specific background mutation frequencies. Additionally MutSig prioritizes mutations that are positionally clustered or occur in highly conserved regions40,42,43. We analyzed mutational spectra and rates across multiple tumor types using previously described methods14.

Mutation clonality analysis. To assess whether mutations are clonal (i.e., present in all cancer cells), we assessed the CCF of each mutation, as described in Carter et al.44. Mutations for which the CCF is close to 1 are considered clonal. Those mutations with lower probable CCFs are considered subclonal. To determine the CCF, we first calculated the sample purity (i.e., the percentage of tumor cells in our sample) by constructing the probability density function for the allele fractions of mutations. Using that information, we then identified a clonal heterozygous peak at or below 0.5 allele fraction:

$$pdf(af) = \sum_{m} \beta_{pdf}(af, alt(m) + 1, ref(m) + 1)$$

where af is the true allele fraction between 0 and 1, alt is the alternate allele counts, ref is the reference allele counts and m is the index for mutation count44. We assumed that the local copy number at each mutation is 2 for craniohypophyngioma and that each tumor has heterozygous clonal mutations that are sufficient to form a peak45,46. Given these assumptions, the purity is the peak af > 2. Thus, mutation clonality analysis is performed as follows: Once we estimated tumor purity, we then estimated the CCF for each mutation. The CCF is the percentage of tumor cells harboring a given mutation. Clonal mutations have a true CCF of 1, and subclonal mutations have a true CCF <1. The observed allele counts correspond to a probability density of the CCF, which can be estimated with the following equation44:

$$pdf(CCF, m) = \beta_{pdf}\left(CCF, CN(m) \times purity(alt(m)), 1, ref(m) + 1\right)$$

where CN(m) is the local copy number at the given mutation m, and CCF ranges from 0 to 1. The probability for any allele fraction greater than the maximum CCF allowed was folded back to a CCF of 1. We again assumed a copy number of 2 (ref. 26,27). We also considered the possibility that the site is homozygous in both copies of the chromosome (loss of heterozygosity) by multiplying the CCF by 2 in the equation above and chose the solution with the highest peak probability. The CCF formulation is approximately equivalent to ABSOLUTE44. The pdfs also provided a direct estimate of the confidence intervals on CCF. Each mutation was classified as clonal or subclonal on the basis of the probability that the CCF exceeded 0.80. A probability threshold of 0.5 was used throughout for this classification47.

Validation of candidate mutations by Sequenom genotyping and SNaPshot. We validated all of the common mutations in BRAF and CTNBN1 by mass spectrometric genotyping based on the Sequenom MassARRAY technology (Sequenom Inc, San Diego, CA) using a multibase homogenous Mass-Extend (hME) as previously described35,48. The complete hME assay list is provided in Supplementary Table 3. A second targeted sequencing platform (SNaPshot genotyping) was performed as previously described to validate the BRAF p.Val600Glu (c.1799T>A) alteration in all papillary craniohypophyngiomas33,49,50.

IHC. We performed immunohistochemical studies on 5-μm-thick whole-tissue sections of formalin-fixed paraffin-embedded tissue in a Bond 3 automated immunostainer (Leica Microsystems, Bannockburn, IL, USA) using a primary antibody against BRAF p.Val600Glu (clone VE1, 1:100, Spring Bioscience, Pleasanton, CA) and a primary antibody against β-catenin (see below). For BRAF p.Val600Glu, we deparaffinized the sections on the Leica Bond using Bond Dewax solution and performed antigen retrieval with an ethylenediaminetetraacetic acid–based solution (Leica) at pH 9 and a Leica Polymer Refine kit for DAB (diaminobenzidine) staining. Appropriate positive and negative controls were included. Positive staining was characterized by diffuse and moderate cytoplasmic staining of the tumor cells. We considered isolated nuclear staining, weak staining of occasional cells or faint diffuse staining as negative staining. For β-catenin (BD Pharmingen, 610154, mouse monoclonal, clone 14), antigen retrieval was performed in a pressure cooker in citrate buffer (pH 6.0, 1:1,000 dilution) with a 45-min incubation followed by Dako anti-mouse horseradish peroxidase for 30 min at room temperature. Cases with nuclear staining (which ranged from low level to high level) were scored as positive, and cases with membranous staining were scored as negative.

36. Demichelis, F. et al. SNIP panel identification assay (SPIA): a genetic-based assay for the identification of cell lines. Nucleic Acids Res. 36, 2446–2456 (2008).
37. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
38. DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
39. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297–1303 (2010).
40. Chapman, M.A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467–472 (2011).
41. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214–220 (2011).
42. Lohr, J.G. et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc. Natl. Acad. Sci. USA 109, 3879–3884 (2012).
43. Stansky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157–1160 (2011).
44. Carter, S.L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413–421 (2012).
45. Rickert, C.H. & Paulus, W. Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas. J. Neurol. Neurosurg. Psychiatry 74, 260–261 (2003).
46. Yoshimoto, M. et al. Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literature. J. Neurosurg. 101, 85–90 (2004).
47. Landau, D.A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714–726 (2013).
48. Thomas, R.K. et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 39, 347–351 (2007).
49. Corcoran, R.B. et al. Braf gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the Braf V600E mutation. Sci. Signal. 3, ra84 (2010).
50. Dias-Santagata, D. et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol. Med. 2, 146–158 (2010).